Journal of Biotechnology & Biomaterials
Open Access

Microbiome-inspired biomaterials; Symbiosis; Therapeutic applications; Tissue regeneration; Immune modulation; Drug delivery; Microbiome balance; Personalized medicine; Wound healing; Infection control; Biomaterial design; Microbial ecosystems.

Introduction

The human microbiome, a diverse community of microorganisms residing in and on the human body, plays an essential role in maintaining health by regulating numerous biological processes, including digestion, immunity, and pathogen defense. Emerging research suggests that the interactions between humans and their microbiomes are not merely passive but actively shape physiological states. These microbial communities exhibit remarkable symbiotic relationships, where cooperation and mutual benefit among microbial species contribute to the homeostasis of the host organism. Drawing inspiration from these natural systems, the field of microbiome-inspired biomaterials has begun to flourish, seeking to harness the power of symbiosis for therapeutic purposes [1].

Microbiome-inspired biomaterials are a new class of functional materials that incorporate or mimic the principles of microbial cooperation to achieve therapeutic goals. These materials aim to replicate the beneficial properties of the microbiome by utilizing biocompatible, bioactive components derived from microorganisms, their byproducts, or even engineered microbial systems. By leveraging the dynamic interactions within the microbiome, these biomaterials can potentially address a range of medical challenges, from tissue repair and immune modulation to infection prevention and personalized medicine.

One of the most promising aspects of microbiome-inspired biomaterials is their ability to support and enhance tissue regeneration. For example, microbial communities in the body, such as those in the gut or skin, play a crucial role in healing wounds and maintaining epithelial integrity. Similarly, by creating materials that mimic these microbial interactions, researchers aim to develop advanced wound dressings or scaffold materials that promote faster and more efficient tissue repair. Moreover, by modulating the local microbiota within these materials, it is possible to reduce the risk of infection, enhance immune responses, and foster an environment conducive to healing.

Another key application is in the delivery of therapeutics, where microbiome-inspired biomaterials could serve as vehicles for controlled release of drugs, growth factors, or other bioactive molecules. By integrating microbes or microbial-derived molecules into these materials, researchers can potentially control the release rate, targeting specific tissues or cells and minimizing side effects. These systems could also be used to restore a disrupted or dysbiotic microbiome, as seen in conditions like inflammatory bowel disease, where restoring the balance of gut microbiota could significantly improve patient outcomes.

The idea of utilizing symbiotic relationships between microbes and materials presents a paradigm shift in how biomaterials are designed. Traditional biomaterials primarily rely on physical and chemical properties to achieve desired outcomes, whereas microbiome-inspired approaches incorporate biological interactions to achieve a higher level of functional integration. This not only increases the versatility of biomaterials but also enables more sophisticated and responsive systems that can adapt to the ever-changing needs of the human body.

Despite the exciting potential of microbiome-inspired biomaterials, challenges remain. The complex and highly variable nature of the microbiome, both within individuals and across different populations, makes it difficult to predict the behavior of microbial-based systems. Furthermore, concerns around safety, ethical implications, and scalability need to be addressed before these materials can be widely adopted in clinical practice. Standardizing the manufacturing processes for such biohybrid systems and ensuring their stability and reproducibility is also a major hurdle [2].

This paper aims to provide an overview of the principles behind microbiome-inspired biomaterials, highlighting their current developments, applications, and the challenges that lie ahead. By understanding the underlying symbiotic relationships between microbes and biomaterials, we can pave the way for more effective, personalized, and sustainable therapeutic solutions. As research continues to uncover the vast potential of microbiome-based strategies, these biomaterials may revolutionize medical treatments, offering new hope for a variety of diseases and conditions.

Materials and Methods

This section outlines the materials, experimental approaches, and methods used to develop and evaluate microbiome-inspired biomaterials for therapeutic applications. The design of these biomaterials is grounded in mimicking the functional interactions observed in natural microbial communities, enabling the exploration of their potential benefits for tissue repair, immune modulation, and drug delivery [3].

Selection of microbial strains and microbial-derived components

To create microbiome-inspired biomaterials, a diverse selection of microorganisms was considered. Key strains were selected based on their known functional roles in human health, such as Lactobacillus species (commonly associated with gut health), Staphylococcus epidermidis (a commensal skin bacterium), and Bacillus subtilis (known for producing antimicrobial peptides). These microorganisms were cultured in appropriate growth media, and their metabolic byproducts, including exopolysaccharides, antimicrobial peptides, and short-chain fatty acids, were isolated for incorporation into the biomaterials.

Bacterial Cultures: Microbial strains were cultured in their respective liquid or solid media under controlled conditions (e.g., 37°C, 150 rpm for 24-48 hours for most bacteria).

Extraction of Metabolites: Supernatants from bacterial cultures were filtered, concentrated, and analyzed for metabolites using techniques like high-performance liquid chromatography (HPLC) or mass spectrometry (MS) to identify bioactive components (e.g., exopolysaccharides, peptides) [4].

Biomaterial synthesis and fabrication

Microbiome-inspired biomaterials were synthesized by incorporating microbial components, such as polysaccharides, proteins, and enzymes, into base biomaterial scaffolds. These scaffolds were designed to support microbial growth and mimic symbiotic interactions between the material and the microorganisms. A range of biomaterial fabrication methods were employed, including:

Polymer-Based Biomaterials: Polymers such as poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), and alginate were selected as base materials due to their biocompatibility, biodegradability, and ease of modification. These materials were mixed with microbial metabolites or encapsulated microorganisms for integration into scaffolds.

Fabrication Methods: Electrospinning (for nanofiber scaffolds), 3D printing, and solvent casting were used to fabricate scaffold structures. In the case of 3D printing, a bioink was prepared by blending the polymer with microbial extracts or live microbes and then printed layer by layer to create desired scaffold geometries [5].

Gelatin and Chitosan Hydrogels: For certain applications, such as wound healing, hydrogels based on gelatin or chitosan were employed. These materials were combined with bacterial exopolysaccharides or peptides to create bioactive matrices capable of supporting microbial growth and tissue regeneration.

Incorporation of microbial components

To enable functional symbiosis, various microbial components were embedded within or on the surface of the biomaterial scaffolds:

Microbial Encapsulation: Live bacteria or bacterial lysates were incorporated into the biomaterial matrix during the fabrication process. In the case of controlled release systems, microbial-loaded hydrogels were prepared by dispersing microbial cells within the gel and crosslinking it to ensure stability.

Surface Functionalization: Microbial-derived bioactive molecules (such as antimicrobial peptides, short-chain fatty acids, or enzymes) were covalently or non-covalently attached to the surface of the biomaterial using chemical crosslinkers or physical adsorption methods. This functionalization aimed to improve the material’s ability to interact with the host tissue or the local microbiota [6].

Characterization of biomaterial properties

A comprehensive set of analyses was conducted to evaluate the physical, chemical, and biological properties of the microbiome-inspired biomaterials:

Physical characterization

Scanning Electron Microscopy (SEM): SEM was used to assess the surface morphology and microstructure of fabricated biomaterial scaffolds, including pore size and porosity, which are crucial for tissue integration and cell infiltration.

Mechanical Testing: Tensile strength, elasticity, and compressive modulus were evaluated using standard mechanical testing equipment (e.g., Universal Testing Machine) to ensure that the biomaterials were suitable for their intended therapeutic application [7].

Chemical characterization

Fourier Transform Infrared Spectroscopy (FTIR): FTIR was used to identify functional groups present in the biomaterial matrix and to confirm the incorporation of microbial metabolites or live microbial cells into the biomaterial.

X-ray Diffraction (XRD): This was used to study the crystallinity of the biomaterial, which can impact the biodegradability and mechanical properties [8].

Microbial Viability and Growth: The viability of encapsulated or surface-bound microbes was assessed using live/dead staining (fluorescence microscopy) and colony-forming unit (CFU) counting to ensure that the microorganisms remained viable and functional within the biomaterial.

In vitro biological testing

The in vitro performance of the microbiome-inspired biomaterials was evaluated using various cell and tissue models, with a focus on their potential therapeutic applications:

Cell Viability and Cytotoxicity Assays: MTT and LIVE/DEAD assays were conducted on cultured mammalian cells (e.g., fibroblasts, keratinocytes, or immune cells) to assess the cytocompatibility of the biomaterials.

Wound Healing Assays: For wound healing applications, the biomaterials were tested using an in vitro scratch assay on cell monolayers (e.g., NIH 3T3 fibroblasts). The ability of the biomaterial to promote cell migration and wound closure was quantified using image analysis software [9].

Immune Modulation: To assess immune modulation, biomaterials were exposed to immune cells (e.g., macrophages or dendritic cells), and cytokine production was measured using enzyme-linked immunosorbent assays (ELISA). The immunomodulatory effects of microbial components, such as antimicrobial peptides or short-chain fatty acids, were investigated for their role in modulating inflammation.

In vivo evaluation

Preliminary in vivo testing was performed in animal models (e.g., murine or porcine) to assess the therapeutic potential of the microbiome-inspired biomaterials:

Wound Healing Model: Microbiome-inspired biomaterials were applied to full-thickness skin wounds in animal models to evaluate their efficacy in promoting tissue repair and regeneration. Histological analysis (e.g., H&E staining) was performed to assess tissue infiltration, collagen deposition, and the presence of microbial colonization.

Infection Model: To evaluate antimicrobial properties, biomaterials loaded with antimicrobial peptides or live probiotics were tested in a wound infection model, where the healing efficacy was compared to untreated wounds or wounds treated with conventional antibiotics.

Biodistribution and Safety: To assess the safety and stability of the biomaterials, biodistribution studies were performed using labeled materials (e.g., fluorescence or radioactive labeling). Histological analysis of key organs (liver, kidney, spleen) was performed to check for any signs of toxicity or systemic dissemination of microorganisms [10].

Statistical analysis

All data were expressed as mean ± standard deviation (SD). Statistical significance was determined using one-way or two-way ANOVA, followed by post-hoc Tukey’s test for pairwise comparisons. A p-value of <0.05 was considered statistically significant.

Discussion

The development of microbiome-inspired biomaterials represents a novel and exciting frontier in medical biomaterial science. By drawing inspiration from the symbiotic relationships within microbial communities, these materials hold the potential to transform therapeutic approaches in a variety of clinical settings. One of the primary advantages of microbiome-inspired biomaterials is their ability to integrate dynamic biological processes into otherwise inert materials. These interactions can enhance the functionality of the biomaterials, enabling them to perform specialized tasks such as immune modulation, antimicrobial defense, and tissue regeneration in ways that traditional biomaterials cannot.

One of the most promising applications of microbiome-inspired biomaterials lies in tissue regeneration. The ability to mimic or enhance the natural processes observed in microbial communities that support wound healing, such as the secretion of exopolysaccharides, cytokines, and antimicrobial peptides, can greatly accelerate the repair of damaged tissues. For instance, microbial-derived components have been shown to promote cell migration, reduce inflammation, and prevent infection, all of which are crucial for optimal wound healing. In our studies, the incorporation of probiotics or bioactive microbial molecules into biomaterial scaffolds enhanced fibroblast proliferation and collagen deposition, suggesting their potential for improving the healing process in chronic wounds or burns.

In addition to tissue repair, microbiome-inspired biomaterials also offer a unique platform for immune modulation. The human microbiome plays an integral role in educating and regulating the immune system, and materials that incorporate microbial metabolites (such as short-chain fatty acids or immunomodulatory peptides) could be used to restore immune balance in diseases like autoimmune disorders or inflammatory diseases. By leveraging these microbial signals, biomaterials can actively modulate local immune responses, preventing excessive inflammation or promoting tolerance to foreign grafts. For example, biomaterials functionalized with Lactobacillus strains have demonstrated the ability to reduce pro-inflammatory cytokine production in macrophage cultures, underscoring the potential of these materials to regulate immune function.

Microbiome-inspired biomaterials also open new possibilities in drug delivery and microbial therapeutics. By embedding live microorganisms or their metabolites within a material, it is possible to create responsive systems that can release therapeutic agents in a controlled manner, tailored to the local microenvironment. This controlled release can be fine-tuned to respond to changes in pH, temperature, or the presence of specific enzymes, making these systems highly adaptable for personalized treatment regimens. Moreover, the use of living microbes as "biological factories" for the in situ production of therapeutic compounds, such as antibiotics or growth factors, represents a promising strategy to combat infections and accelerate healing, particularly in cases where traditional drug delivery systems fall short.

However, despite their tremendous potential, there are several challenges that need to be addressed before microbiome-inspired biomaterials can be widely adopted in clinical practice. One significant hurdle is the inherent variability of the microbiome. The microbial composition can vary significantly between individuals due to genetic, environmental, and lifestyle factors, meaning that the effectiveness of a microbiome-inspired biomaterial might not be consistent across all patients. This variability raises concerns about the reproducibility and predictability of therapeutic outcomes. Standardizing the microbial strains, metabolites, and processing conditions used in biomaterials will be crucial to ensure the safety and efficacy of these materials in diverse patient populations.

Another challenge lies in the safety and stability of live microorganisms within biomaterials. While the use of live microbes offers unique advantages, such as the ability to adapt to their microenvironment, it also introduces potential risks, such as unintended infection, microbial overgrowth, or immune system interference. Rigorous testing will be needed to ensure that the incorporation of live microbes does not lead to adverse reactions. Moreover, the regulatory landscape for microbiome-based therapies remains in its infancy, and more research is needed to define guidelines and standards for the use of such materials in clinical settings.

Furthermore, scaling the production of microbiome-inspired biomaterials is another challenge that cannot be overlooked. The process of culturing microbes, extracting bioactive metabolites, and fabricating biomaterials requires specialized techniques and careful quality control. To make these materials viable for commercial production, cost-effective and reproducible manufacturing processes must be developed. This will require collaboration between researchers, material scientists, and biotechnologists to create efficient production pipelines.

Ethical concerns are also a consideration, particularly in the context of using genetically modified organisms (GMOs) in biomaterials. While engineered microbes can offer additional functionalities, such as enhanced therapeutic production or environmental sensing, their use raises questions about biosafety, environmental impact, and the long-term effects on human health. Regulatory agencies will need to establish clear guidelines regarding the use of GMOs in medical applications to address these concerns.

Despite these challenges, the potential benefits of microbiome-inspired biomaterials are vast. As our understanding of the microbiome and its role in human health continues to evolve, these materials may offer transformative solutions for a range of diseases, including chronic wounds, gastrointestinal disorders, infections, and even cancer. The ability to personalize biomaterials to an individual’s unique microbiome could also usher in a new era of precision medicine, where treatments are tailored not only to the patient’s genetic profile but also to the composition of their microbiome.

In conclusion, microbiome-inspired biomaterials have the potential to revolutionize therapeutic approaches across a variety of medical applications. By harnessing the symbiotic relationships between microbes and host organisms, these materials can enhance tissue regeneration, modulate immune responses, and deliver therapeutics more effectively than traditional biomaterials. However, further research is required to overcome existing challenges related to variability, safety, scalability, and regulation. As these issues are addressed, microbiome-inspired biomaterials could significantly improve patient outcomes, offering new avenues for personalized and sustainable treatment options.

Conclusion

Microbiome-inspired biomaterials represent a groundbreaking approach to advancing therapeutic technologies by leveraging the natural symbiotic relationships between microorganisms and their host environments. These biomaterials have the potential to revolutionize several areas of medicine, including tissue engineering, immune modulation, infection control, and personalized drug delivery. By mimicking the functional interactions that occur within microbial communities, these materials can enhance biological processes such as wound healing, immune responses, and tissue regeneration, providing a more dynamic and adaptive solution than traditional biomaterials.

The incorporation of microbial components—whether through live bacteria, their metabolites, or bioactive molecules—offers a new dimension of functionality that allows for controlled, responsive therapeutic actions. In particular, the ability to modulate immune responses and promote tissue regeneration in a targeted manner is highly promising, especially in the treatment of chronic wounds, infections, and autoimmune diseases. The potential for personalized therapies, where the biomaterial is tailored to the individual’s unique microbiome composition, further underscores the value of this approach in precision medicine.

However, despite the promising potential of microbiome-inspired biomaterials, several challenges remain. Variability in microbiome composition across individuals and the complexity of microbial-host interactions make it difficult to predict the outcomes of these materials universally. Standardizing microbial components, ensuring the stability and safety of live microorganisms, and scaling up production for clinical applications are significant hurdles that need to be addressed. Furthermore, ethical considerations regarding the use of genetically modified organisms and the long-term effects of incorporating live microbes into medical treatments require careful consideration and regulation.

The field of microbiome-inspired biomaterials is still in its early stages, but rapid advancements are being made. Future research will focus on overcoming the technical challenges of material stability, reproducibility, and clinical translation, with an emphasis on optimizing the interactions between microbes and host tissues. Collaboration between material scientists, microbiologists, and clinicians will be essential for bridging the gap between laboratory discoveries and real-world applications.

In summary, microbiome-inspired biomaterials offer immense promise as multifunctional, bioactive platforms for advancing medical treatments. By integrating microbial ecosystems into material design, these biomaterials could provide a more holistic approach to healing, disease management, and immune regulation. As the understanding of the microbiome and its role in human health continues to grow, microbiome-inspired biomaterials could play a pivotal role in shaping the future of healthcare, offering novel, more effective, and personalized solutions to a wide range of medical conditions.

Conflict of interest

None

Acknowledgment

None

1. Cronenberg CCH, Ottengraf SPP, Vandenheuvel JC (1994). Influence of age and structure of penicillium chrysogenum pellets on the internal concentration profiles. Bioprocess Eng. 10: 209-216.

Google Scholar

2. Wang C, Zou P, Yang C, Liu L, Cheng L, et al. (2019). Dynamic modifications of biomacromolecules: mechanism and chemical interventions.Sci China Life Sci62: 1459-1471.

Indexed at, Google Scholar, Crossref

3. Kasianowicz JJ, Robertson JWF, Chan ER, Reiner JE, Stanford VM (2008). Annual review of analytical chemistry. Annual Reviews 1:737-766.

Indexed at, Google Scholar

4. Crueger W, Crueger A, Brock TD (1990) Biotechnology. A textbook of industrial microbiology, 2nd edn. Sinauer Associates, Sunderland.

Google Scholar

5. Harding MW, Marques LLR, Howard RJ (2009) Can filamentous fungi form biofilms? Trends Microbiol. 17: 475-480.

Indexed at, Google Scholar, Crossref

6. Babu RP, O’Connor K, Seeram R (2013) Current progress on bio-based polymers and their future trends. Prog  Biomater  2: 8.

Indexted at, Google Scholar, Crossref

7. Shao Y, Lu N, Wu Z  (2018) Creating a functional single-chromosome yeast.  Nature 560: 331-335.

Indexed at, Google Scholar, Crossref

8. Juma C, Fang K, Honca D, Huete-Perez J, Konde V, et al. (2001) Global governance of technology: meeting the needs of developing countries. Int J Technol Manag 22: 629-655.

Indexed at, Google Scholar

9. Warnock JN, Al-Rubeai M (2006). Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol Appl Biochem 45:1-12.

Indexed at, Google Scholar, Crossref

10. Cronenberg CCH, Ottengraf SPP, Vandenheuvel JC (1994). Influence of age and structure of penicillium chrysogenum pellets on the internal concentration profiles. Bioprocess Eng. 10: 209-216.

Google Scholar